Treatment of breast cancer with bone metastasis: Bisphosphonate treatment - Current and future

International Journal of Clinical Oncology

Volumn 13, Issue 1, 2008, Pages 18-23

  Kohno, Norio ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Bone metastases; Breast cancer

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER PREVENTION; CLINICAL TRIAL; DRUG INHIBITION; DRUG MECHANISM; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; OSTEONECROSIS;

EID: 40149105373     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0726-2     Document Type: Review

References (42)

1. Arams HL, Spiro R, Goldstein M (1950) Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 3:74-76
2. Galasko C (1981) The anatomy and pathways of bone metastases. In: Weiss L, Gilbert A (eds) Bone metastases. GK Hall, Boston, pp 49-63
3. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66
4. Conte P, Colman R (2004) Bisphosphonate in the treatment of skeletal metastases. Semin Oncol (Suppl 10) 31:59-63
5. Fleish H (2000) Bisphosphonates in bone disease. Academic Press, A Harcourt Science and Technology, San Diego, p 40
6. Rogers MJ (2003)New insights into the molecular mechanism of action of bisphosphonates. Curr Pharm Design 9:2643-2658
7. Cle'zardin P, Fournier P, Boissier S, Perryruchaud O (2003) In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10:173-180
8. Green J (2003) Antitumor effects of bisphosphonates. Cancer 97:840-847
9. Coxon JR, Oades GM, Kirby RS, Colston KW (2004) Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94:164-170
10. Cle'zardin P, Ebetino F, Fournier P (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65:4971-4974
11. Denoyelle C, Hong L, Vannier JP, et al. (2003) New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and-independent effects. Br J Cancer 88:1631-1640
12. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. (2005) Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 11:364-371
13. Fourtmier P, Boissier S, Filleur S, et al. (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544
14. Gober HJ, Kistowska M, Angman L, et al. (2003) Human T cell receptor γδ cells recognize endogenous mevalonate metabolite in tumor cells. J Exp Med 197:163-168
15. Theriault RL, Lipton A, Hortobagyi GN, et al. (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854
16. Hortobagyi GN, Theriault RL, Lipton A, et al. (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044
17. Body JJ, Diel IJ, Lichinitser MR, et al. (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405
18. Body JJ, Diel IJ, Lichinitzer MR, et al. (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90:1133-1137
19. Kohno N, Aogi K, Minami H, et al. (2005) Zoledronic acid signi-ficantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 20;23:3314-3321.
20. Anderson PK, Grill RD (1982) Cox's regression model for counting processor: a large sample study. Am Stat 10:1100-1120
21. Rosen LS, Gordon D, Kaminski M, et al. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744.
22. Pavlakis N, Schmidt RL, Stockler M (2005) Bisphosphonate for breast cancer (review) Cochrane Database Syst Rev CD003474; 1-40
23. Hillner BE, Ingle JN, Chlebowski RT, et al. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057
24. Sasaki A, Boyce BF, Wright KR, et al. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557
25. Yoneda T, Sasaki A, Dunstan C, et al. (1997) Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99:2509-2517
26. Green J, Gshaidmeier H, Yoneda T, et al. (2000) Zoledronic acid inhibits tumor induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 11(Suppl 4):14
27. Hiraga T, Williams PJ, Mundy GR, et al. (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61:4418-4424
28. Hiraga T, Williams PJ, Ueda A, et al. (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10:4559-4567
29. Diel IJ, Solomayer EF, Bastert G, et al. (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363
30. Jaschke A, Bastert G, Solomayer EF, et al. (2004) Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-A longtime follow-up. Abstract 527. Proc Am Soc Clin Oncol 23:9
31. Powels T, Paterson A, Kanis J, et al. (2004) Oral clodronate for adjuvant treatment of operable breast cancer; results of a randomized, double-blind, placebo-controlled multicenter trial. (abstract 528) Proc Am Soc Clin Oncol 23:9
32. Saarto T, Vehmanen L, Virkkunen P, et al. (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656
33. Kokufu I, Kohno N, Takao S, et al. (2004) Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancr (BC) patients (pts) with four or more positive nodes. Abstract 530 Proc Am Soc Clin Oncol 23:8
34. Clemons M, Rea D (2004) Perspective on the future of bisphosphonate use in breast cancer patients. Semin Oncol 31:87-91
35. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1157
36. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. (2004) Osteonecrosis of the jaws associated with the use of bisphosphonate: a review of 63 cases. J Oral Maxillofac Surg 62:527-534
37. Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761
38. Marx RE, Sawatari Y, Fortin M, et al. (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63:1567-1575
39. Melo MD, Obeid G (2005) Osteonecrosis of the jaws in patients with history of receiving bisphosphonate therapy. J Am Dent Assoc 136:1675-1681
40. Bamias A, Kastritis E, Bamia C, et al. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580-8587
41. Expert panel recommendations for prevention, diagnosis, and treatment of osteonecrosis of the jaws: June 2004 (2004) Professional education material. Novartis, East Hanover, NJ
42. Body JJ, Facon T, Coleman RE, et al. (2006) A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12;1221-1228